(Q34397832)

1 August 2017

1 reference

title

What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes? (English)

1 reference

1 August 2017

Waters DD

1

1 reference

1 August 2017

Hsue PY

series ordinal

2

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

American Journal of Cardiology

1 August 2017

published in

1 reference

1 August 2017

volume

88

1 reference

1 August 2017

issue

7B

1 reference

1 August 2017

page(s)

7J-16J

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Early statin treatment following acute myocardial infarction and 1-year survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Cholesterol lowering. Should it continue to be the last thing we do?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Differential progression of complex culprit stenoses in patients with stable and unstable angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Aspirin, heparin, or both to treat acute unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Platelet GPIIb-IIIa blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

A critical appraisal of platelet glycoprotein IIb/IIIa inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Close relation of endothelial function in the human coronary and peripheral circulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Cracking down on caveolin: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in modulating edothelial cell nitric oxide production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Vasoreactivity of the culprit lesion in unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Platelet function in hyperlipoproteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Effect of cholesterol on production of thromboxane b2 by platelets in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Increased thromboxane biosynthesis in type IIa hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events i

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901921-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(01)01921-X

1 reference

1 August 2017

1 reference